Relief Initiates Leadership Change
November 22, 2023
Rare Daily Staff
Relief Therapeutics named Michelle Lock, an experienced pharmaceutical executive and current independent member of Relief’s board of directors, as its interim CEO.
She replaces Relief CEO Jack Weinstein, who stepped down as part of a leadership transition.
Relief is a commercial-stage biopharmaceutical company focused on rare disease therapies. Its portfolio offers a mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic and TEHCLO platform technologies and a targeted clinical development pipeline in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases.
“Michelle has been an active and insightful member of our board of directors. Her deep understanding of our organization and her extensive leadership experience in both biotech and big pharma settings make her an ideal leader for Relief.” said Raghuram Selvaraju, chairman of the board of Relief.
Lock previously held executive roles as chief operating officer of Covis Pharma Group and senior vice president and head of Europe and International at Acceleron Pharma. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience and spent 24 years with Bristol-Myers Squibb.
Sign up for updates straight to your inbox.